Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Currently, molecular testing occurs at the tail end of the diagnostic workflow for inherited bleeding disorders.
Variation in disease phenotype and clinical circumstances makes it difficult to create a standardized treatment approach to von Willebrand disease.
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Identifying patients with smoldering myeloma at high risk for disease progression may allow for implementation of better treatment strategies.
Proteasome inhibitors and immunomodulatory drugs have demonstrated improvements in survival and response in patients with multiple myeloma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
Treatment with erythropoietin-stimulating agents may yield improved hematopoietic responses and reduce the need for red blood cell transfusions.
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
High shear stress in blood vessels due to cardiovascular disease may be associated with the development of acquired von Willebrand syndrome.
Because most studies on heavy menstrual bleeding have been conducted in adults, treatment guidelines for adolescents are lacking.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
With advances in cancer research and treatments, patients with acute lymphoblastic leukemia (ALL) can enjoy longer lives and treatment can continue long after initial hospital admission and into the outpatient setting.1,2 Parents of children with leukemia often find themselves serving as direct caregivers for their children, an important role that may require them to receive…
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Transgender women receiving hormone replacement therapy may be at an increased risk for thromboembolism, though data and recommendations vary across studies.
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
Population-based screening of newborns is crucial to identifying severe combined immunodeficiency before the onset of potentially fatal infection.
Because dysregulation of coagulation is a key feature of thromboinflammation, coagulation inhibitors may have therapeutic potential.
Several factors need to be considered when determining whether a child’s bleeding symptoms are the result of a coagulation disorder, physical abuse, or both.
Despite deeper understanding of some of the molecular mechanisms underlying Diamond-Blackfan anemia, the search for effective therapies is ongoing.
A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.
Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.
There are currently limited data to inform an optimal treatment strategy for cytokine release syndrome, a common complication of CAR T therapy.
Though imaging provides a powerful tool for diagnosis and treatment of multiple myeloma, choosing the appropriate technique depends on many factors.
Non-GVHD ocular complications can seriously affect patient morbidity and quality of life following hematopoietic cell transplantation.
Changes in clinical management of trauma hemorrhage have significantly reduced mortality rates, but variation in treatment strategies still remains.